Compare SELF & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | INKT |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.0M | 53.7M |
| IPO Year | 1997 | 2021 |
| Metric | SELF | INKT |
|---|---|---|
| Price | $4.88 | $8.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.15 | ★ $44.00 |
| AVG Volume (30 Days) | ★ 19.1K | 10.2K |
| Earning Date | 11-06-2026 | 11-11-2026 |
| Dividend Yield | ★ 5.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $12,705,245.00 | N/A |
| Revenue This Year | $1.53 | N/A |
| Revenue Next Year | $1.22 | N/A |
| P/E Ratio | $32.37 | ★ N/A |
| Revenue Growth | ★ 1.40 | N/A |
| 52 Week Low | $4.74 | $8.48 |
| 52 Week High | $5.75 | $15.27 |
| Indicator | SELF | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 33.82 |
| Support Level | $4.80 | N/A |
| Resistance Level | $5.26 | $11.92 |
| Average True Range (ATR) | 0.09 | 0.73 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 40.12 | 10.85 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.